Wolverine Stack
Also known as: BPC-157/TB-500 combination, Wolverine blend
BPC-157 + TB-500 | Tissue Repair & Recovery Protocol
Overview
Combines BPC-157 and TB-500 for synergistic tissue repair and recovery. 87.5% improvement in knee pain patients per Lee & Padgett 2021 study.
Key benefits
- Complementary healing mechanisms
- 87.5% improvement in knee pain patients
- Reduced inflammation and enhanced cell migration
- Promotes angiogenesis and reduces scarring
Mechanism of action
BPC-157 increases actin production and modulates nitric oxide for vascular effects; TB-500 sequesters actin for cell migration; synergistic enhancement of fibroblast and immune cell movement to injury sites.
Molecular data
- Type
- Peptide blend
Sequence
N/A
Indications
What the research community uses this compound for, with self-reported effectiveness.
Tissue Repair
Wound Healing
Anti-Inflammatory
Dosing protocols
Common protocols by delivery method. Adjust the curve below to model accumulation in your own cycle.
Delivery method
| Protocol | Dose | Frequency | Duration |
|---|---|---|---|
| — | BPC-157: 250mcg 2x/day + TB-500: 2mg 2x/week | BPC-157 daily, TB-500 twice weekly | — |
| — | BPC-157: 500mcg 2x/day + TB-500: 2.5mg 2x/week | BPC-157 daily, TB-500 twice weekly | — |
| — | BPC-157: 250mcg 1x/day + TB-500: 2mg 1x/week | BPC-157 daily, TB-500 weekly | — |
Delivery method
| Protocol | Dose | Frequency | Duration |
|---|---|---|---|
| — | BPC-157: 500mcg-1mg | Once daily on empty stomach | — |
Safety
Reported adverse effects, contraindications, and what to monitor on cycle.
Common side effects
- Not extensively documented in human studies
- Generally well-tolerated in available research
Contraindications
- ANY history of cancer or suspicious growths
- Active malignancy or concurrent chemotherapy
- Pregnancy or breastfeeding
Monitoring
- Tissue growth or changes
- Injection site reactions
- Allergic responses
- Bleeding episodes
- Not FDA approved—research chemical only
- Banned by WADA and major sports organizations
References
Primary literature and clinical-trial data informing this entry.